Stirling Products of Perth, Australia, today announced that its wholly owned North American subsidiary, Stirling Products North America (STI-NA) successfully completed product trials in shrimp with a global animal pharmacology company for applications of ProVale, an immune-stimulating bioactive extract.
STI-NA entered into an agreement with the pharmacology company in July 2007 and conducted validation trials in shrimp in Southeast Asia. The findings show ProVale improves survival rates and overall yield of shrimp under stressful conditions.
"ProVale has previously been shown to increase the production in shrimp ponds by more than 36 percent and decrease the mortality of shrimp due to disease by more than 28 percent," says Shane Patelakis, president of STI-NA. "The latest trials confirm the ability of ProVale to significantly improve production yield and survival of commercially raised shrimp even under challenged conditions."
The pharmacology company now will conduct its required due diligence while both parties negotiate an appropriate agreement for the worldwide rights to formulate, distribute and/or commercialize ProVale for shrimp.
